newsfilter
← Latest News
GlobeNewswire·

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

DENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that